Veriheal

DECEMBER 27, 2022

Let’s dive into what the research says about these promising new findings and how they might advance the field of psychedelic research. Some research suggests that these substances could be used to treat mental health conditions like depression and anxiety. The subjective nature of self-reported data can plague research.

Research and Development 95

Research and Development Therapy Consumption DEA 95

Veriheal

AUGUST 24, 2022

If passed, the Department of Regulatory Agencies would be required to develop rules that would allow for therapeutic psychedelic programs at licensed healing centers for adults to receive psychedelic treatments by a trained facilitator. Research and Testimonials Point to Psychedelics’ Therapeutic Benefits.

Legalization 108

Legalization Medicine Decriminalization Research and Development 108

Veriheal

JUNE 24, 2021

health official reportedly slammed “ongoing federal restrictions that are inhibiting research into marijuana”. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. branch of Aphria, Inc.,

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Psychedelic therapy is not a fringe phenomenon.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

AUGUST 12, 2022

Obtaining DEA License to Grow Psilocybin Mushrooms. This panel would explore topics such as the ethical implications of psychedelic-based drug development and patenting, as well as the debate over producing and marketing natural versus synthetic psychedelics. Here are some psychedelics panel options: .

Research and Development 52

Research and Development Events Topical Policy 52

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

The Joint Blog

JUNE 4, 2021

Believe it or not, you actually need a license to do meaningful research on marijuana due to the fact that the United States Drug Enforcement Agency (DEA) has limited its access. The DEA feels that marijuana, being a schedule I drug, could be misused like other drugs within that category and could be dangerous.

Conditions 32

Conditions Chronic Pain Marijuana Research and Development 32

Cannabis Law Report

JUNE 15, 2021

. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.

Decriminalization 78

Decriminalization Policy Research and Development Data 78

Cannabis Law Report

JANUARY 30, 2019

Access the full document at. For nearly fifty years, the University of Mississippi has had the sole contract with the National Institute on Drug Abuse (NIDA) to grow cannabis for research purposes. Do you intend to support the expansion of marijuana manufacturers for scientific research? R ESPONSE: Yes.

Research and Development 63

Research and Development DEA CBD Law 63

Cannabis Law Report

APRIL 14, 2022

Although research is still underway, the effects of both short- and long-term exposure to pesticides by consuming (i.e., pursuant to Drug Enforcement Agency (DEA) or state-level programs). by eating or smoking cannabis) are unknown. Indoor grow operations also can create a significant new demand on utility water supply infrastructure.

Environment 52

Environment Agriculture Compliance Compliance 52

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. Patients Are Not In This Alone.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Canna Law Blog

NOVEMBER 6, 2021

Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. But only if it is made affordable and accessible.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

JULY 1, 2021

On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation. POPLAR will publish original law and policy research. What barriers exist to conducting psychedelics research?

Law 105

Law Research and Development Therapy DEA 105

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. See, for example, this comprehensive ketamine infusion therapy checklist developed by the American Association of Nurse Anesthetists.

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

SEPTEMBER 23, 2019

Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). The AAFP urges its members to be involved in the diagnosis, treatment, and prevention of substance use, as well as secondary diseases impacted or caused by use. This process should also ensure appropriate funding allocated for this research.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Canna Law Blog

MARCH 4, 2020

People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. See, for example, this comprehensive ketamine infusion therapy checklist developed by the American Association of Nurse Anesthetists.

Legalization 52

Legalization Therapy Chronic Pain DEA 52

The Cannigma

SEPTEMBER 12, 2021

THC is the most prevalent, famous and researched cannabinoid by far. This contradiction, combined with a problematic regulatory framework that limits access to THC products in many states, has created a booming market for d-8 and d-10. The first researcher who identified and isolated THC, was the American Roger Adams (Shutterstock).

THC 98

THC Research and Development Cannabinoids CBD 98

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

SEPTEMBER 1, 2021

While there has been increasing attention and interest in this issue on Capitol Hill, in the near term the federal tax treatment of cannabis-related business remains fraught with risks. 12] Ultimately, only Congress can amend the CSA itself to remove, or otherwise reform the treatment of cannabis under federal law. August 30, 2021.

Policy 100

Policy Cannabis Treatment Law 100

The Cannigma

MAY 15, 2023

Because ketamine promotes neuroplasticity, or in other words helps “rewire” the brain,” research shows that it can help stop the repetitive negative thoughts and behaviors that are at the core of many mental health conditions. Patients may want to seek assistance from a certified professional prior to embarking on treatment.

Therapy 78

Therapy Access Blood Pressure Treatment 78

The Cannigma

FEBRUARY 16, 2022

To hear more about Steven’s research, what he hopes it will lead to, his predictions for the future of cannabis, how he is helping those most harmed by the war on drugs, and how you can help too, tune in today! So, with that, we should get into it, but don’t forget to check out our segment with Americans for Safe Access.

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73

Cannabis Law Report

APRIL 4, 2022

Congress, signed into law by President Trump, with 41 state enactments, give terminally ill patients access to experimental medicines still in development? But the Drug Enforcement Agency is barring access to one such experimental medicine: psilocybin, also known in its fungal form as “magic mushrooms.”. Read more at.

Access 52

Access Patients DEA Research and Development 52

Kind Meds (Cannabis Education Blog)

FEBRUARY 7, 2022

The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse. The governor of Alabama signed a recreational bill into law in 2021, but patients will likely not have access to retail products until 2022. each year since 2019.

Recreational 52

Recreational Data Cannabis DEA 52

SpeedWeed

DECEMBER 28, 2018

There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval. But there’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval and Big Pharma’s insatiable thirst for profits.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

Cannabis Law Report

JULY 30, 2019

Beasley is forced by default to expand her knowledge base through scientific facts that warrant closer inspection and through accessible existing research, with few current cannabis case studies. Most reliable medical cannabis research filters into the U.S. through international sources, namely Israel. . Federal Register. .

Marijuana 45

Marijuana Patients Research and Development Programs 45

Cannabis Law Report

JULY 14, 2021

“Closing the door on broadly supported incremental reforms like the SAFE Banking Act while the Senate seeks compromise on farther-reaching bills hurts the possibilities for consensus and ignores the very real needs of small business operators who have repeatedly said that access to banking services and traditional lending is an existential issue.

Legislation 71

Legislation Banking History Access 71